Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
N646601-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $80.90 | |
N646601-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $150.90 | |
N646601-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $320.90 | |
N646601-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $540.90 | |
N646601-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $940.90 |
Synonyms | 116409-29-1|NSC-370284|6-(1-Pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl)-1,3-benzodioxol-5-ol|NSC370284|NSC 370284|6-[pyrrolidin-1-yl-(3,4,5-trimethoxyphenyl)methyl]-1,3-benzodioxol-5-ol|6-(Pyrrolidin-1-yl(3,4,5-trimethoxyphenyl)methyl)benzo[d][1,3]dioxol- |
---|---|
Specifications & Purity | ≥96% |
Biochemical and Physiological Mechanisms | NSC-370284 is a selective inhibitor of ten-eleven translocation 1 ( TET1 ) and 5-hydroxymethylcytosine ( 5hmC ). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | NSC-370284 is a selective inhibitor of ten-eleven translocation 1 ( TET1 ) and 5-hydroxymethylcytosine ( 5hmC ). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5 In Vitro NSC-370284 (0-500 nM; 24 h or 48 h) inhibits the viability of MONOMAC-6, THP-1, KOCL-48 and KASUMI-1 acute myeloid leukemia (AML) cells via targeting STAT3/5. NSC-370284 significantly down-regulates the level of TET1 transcription. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: AML cell lines including MONOMAC-6, THP-1, KOCL-48, and KASUMI-1. Concentration: 0, 25, 50, 200 or 500 nM. Incubation Time: 24 h or 48 h. Result: Showed inhibitory for AML cells viability and TET1 transcription. In Vivo NSC-370284 (2.5 mg/kg; i.p., once daily for 10 days) improves the pathological morphologies in peripheral blood (PB), bone marrow (BM), spleen, and liver tissues in MLL-AF9 acute myeloid leukemia (AML) mice model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice . Dosage: 2.5 mg/kg. Administration: Intraperitoneal injection, once daily, for 10 days. Result: Significantly inhibited MLL-AF9 induced AML in secondary bone marrow transplantation (BMT) recipient mice. Form:Solid IC50& Target:STAT3 STAT5 TET1 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 6-[pyrrolidin-1-yl-(3,4,5-trimethoxyphenyl)methyl]-1,3-benzodioxol-5-ol |
---|---|
INCHI | InChI=1S/C21H25NO6/c1-24-18-8-13(9-19(25-2)21(18)26-3)20(22-6-4-5-7-22)14-10-16-17(11-15(14)23)28-12-27-16/h8-11,20,23H,4-7,12H2,1-3H3 |
InChi Key | QCXGNLZKUHBIHD-UHFFFAOYSA-N |
Canonical SMILES | COC1=CC(=CC(=C1OC)OC)C(C2=CC3=C(C=C2O)OCO3)N4CCCC4 |
Isomeric SMILES | COC1=CC(=CC(=C1OC)OC)C(C2=CC3=C(C=C2O)OCO3)N4CCCC4 |
Alternate CAS | 116409-29-1 |
PubChem CID | 340208 |
NSC Number | 370284 |
Molecular Weight | 387.43 |
Enter Lot Number to search for COA:
Solubility | DMSO : 100 mg/mL (258.11 mM; Need ultrasonic) |
---|